Mobile health technologies in an interventional hybrid study on actinic keratosis: Results from an early phase randomized controlled trial investigating the safety and efficacy of a cytosolic phospholipase A2 inhibitor gel in photodamaged skin.
actinic keratosis
cytosolic phospholipase A2 inhibitor
hybrid trial
Journal
Experimental dermatology
ISSN: 1600-0625
Titre abrégé: Exp Dermatol
Pays: Denmark
ID NLM: 9301549
Informations de publication
Date de publication:
Apr 2024
Apr 2024
Historique:
revised:
15
03
2024
received:
29
01
2024
accepted:
19
03
2024
medline:
13
4
2024
pubmed:
13
4
2024
entrez:
13
4
2024
Statut:
ppublish
Résumé
Hybrid trials are a new trend in dermatological research that leverage mobile health technologies to decentralize a subset of clinical trial elements and thereby reduce the number of in-clinic visits. In a Phase I/IIa randomized controlled hybrid trial, the safety and efficacy of an anti-proliferative and anti-inflammatory drug inhibiting cytosolic phospholipase A2 (AVX001) was tested using 1%, 3% or vehicle gel in 60 patients with actinic keratosis (AK) and assessed in-clinic as well as remotely. Over the course of 12 weeks, patients were assessed in-clinic at baseline, end of treatment (EOT) and end of study (EOS), as well as 9 times remotely on a weekly to biweekly basis. Safety outcomes comprising local skin reactions (LSR; 0-5), adverse events (AE) and cosmesis, were graded in-clinic and remotely using patient-obtained smartphone photographs (PSPs) and questionnaires; efficacy was assessed in-clinic based on clinically visible clearance of AK target area of >50%. A total of 55 participants (91.7%) completed the treatment course. The average submission rate of PSPs was high (≥85%), of which 93% were of sufficient quality. No serious AE were reported and only two experienced temporary LSR >2 (scale 0-4) and cosmesis remained stable throughout the study. Based on the mild AE and LSR profile, daily application of AVX001 gel for 1 month appears safe, tolerable, and cosmetically acceptable for use in patients with AK. At EOT, AVX001 achieved a subtle treatment response with clearance of AK target area of >50% in 18% of patients. Remote and in-clinic assessments of LSRs were in high agreement, suggesting that the use of mobile health technologies in early-phase hybrid studies of AK does not compromise patient safety.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15068Subventions
Organisme : Coegin Pharma AB
Informations de copyright
© 2024 The Authors. Experimental Dermatology published by John Wiley & Sons Ltd.
Références
Reinehr CPH, Bakos RM. Actinic keratoses: review of clinical, dermoscopic, and therapeutic aspects. An Bras Dermatol. 2019;94:637‐657.
Carrara IM, Melo GP, Bernardes SS, et al. Looking beyond the skin: cutaneous and systemic oxidative stress in UVB‐induced squamous cell carcinoma in hairless mice. J Photochem Photobiol B. 2019;195:17‐26.
Berhane T, Halliday GM, Cooke B, Barnetson RSC. Inflammation is associated with progression of actinic keratoses to squamous cell carcinomas in humans. Br J Dermatol. 2002;146:810‐815.
Marques E, Chen TM. Actinic keratosis. In: StatPearls. StatPearls Publishing; 2022.
Quaedvlieg PJF, Tirsi E, Thissen MRTM, Krekels GA. Actinic keratosis: how to differentiate the good from the bad ones? Eur J Dermatol. 2006;16:335‐339.
Ahmady S, Jansen MHE, Nelemans PJ, et al. Risk of invasive cutaneous squamous cell carcinoma after different treatments for actinic keratosis: a secondary analysis of a randomized clinical trial. JAMA Dermatol. 2022;158:634‐640.
Tolley K, Argenziano G, Calzavara‐Pinton PG, Larsson T, Ryttig L. Pharmacoeconomic evaluations in the treatment of actinic keratoses. Int J Immunopathol Pharmacol. 2017;30:178‐181.
Noels EC, Hollestein LM, Egmond S, et al. Healthcare utilization and management of actinic keratosis in primary and secondary care: a complementary database analysis. Br J Dermatol. 2019;181:544‐553.
Hensen P, Müller ML, Haschemi R, et al. Predisposing factors of actinic keratosis in a north‐west German population. Eur J Dermatol. 2009;19:345‐354.
de Berker D, McGregor J, Mohd Mustapa MF, Exton LS, Hughes BR. British Association of Dermatologists' guidelines for the care of patients with actinic keratosis 2017. Br J Dermatol. 2017;176:20‐43.
Eisen DB, Asgari MM, Bennett DD, et al. Guidelines of care for the management of actinic keratosis. J Am Acad Dermatol. 2021;85:e209‐e233.
Eisen DB, Dellavalle RP, Frazer‐Green L, Schlesinger TE, Shive M, Wu PA. Focused update: guidelines of care for the management of actinic keratosis. J Am Acad Dermatol. 2022;87:373‐374.e5.
Werner RN, Stockfleth E, Connolly SM, et al. Evidence‐ and consensus‐based (S3) guidelines for the treatment of actinic keratosis – International League of Dermatological Societies in cooperation with the European Dermatology Forum – short version. J Eur Acad Dermatol Venereol. 2015;29:2069‐2079.
Lampley N, Rigo R, Schlesinger T, Rossi AM. Field therapy for actinic keratosis: a structured review of the literature on efficacy, cost, and adherence. Dermatol Surg. 2023;49:124‐129.
Nemer KM, Council ML. Topical and systemic modalities for chemoprevention of nonmelanoma skin cancer. Dermatol Clin. 2019;37:287‐295.
Wenande E, Togsverd‐Bo K, Hastrup A, Lei U, Philipsen PA, Haedersdal M. Skin cancer development is strongly associated with actinic keratosis in solid organ transplant recipients: a Danish cohort study. Dermatology. 2023;239:393‐402. doi:10.1159/000529369
Nasry WHS, Rodriguez‐Lecompte JC, Martin CK. Role of COX‐2/PGE2 mediated inflammation in oral squamous cell carcinoma. Cancers. 2018;10:348.
Feuerherm AJ, Dennis EA, Johansen B. Cytosolic group IVA phospholipase A2 inhibitors, AVX001 and AVX002, ameliorate collagen‐induced arthritis. Arthritis Res Ther. 2019;21:29.
Huwiler A, Feuerherm AJ, Sakem B, et al. The ω3‐polyunsaturated fatty acid derivatives AVX001 and AVX002 directly inhibit cytosolic phospholipase A(2) and suppress PGE(2) formation in mesangial cells. Br J Pharmacol. 2012;167:1691‐1701.
Omland SH, Habicht A, Damsbo P, Wilms J, Johansen B, Gniadecki R. A randomized, double‐blind, placebo‐controlled, dose‐escalation first‐in‐man study (phase 0) to assess the safety and efficacy of topical cytosolic phospholipase A2 inhibitor, AVX001, in patients with mild to moderate plaque psoriasis. J Eur Acad Dermatol Venereol. 2017;31:1161‐1167.
Ashcroft FJ, Mahammad N, Midtun Flatekvål H, Jullumstrø Feuerherm A, Johansen B. cPLA2α enzyme inhibition attenuates inflammation and keratinocyte proliferation. Biomolecules. 2020;10:E1402.
Hsu K‐C, Luan C‐W, Tsai Y‐W. Review of silicone gel sheeting and silicone gel for the prevention of hypertrophic scars and keloids. Wounds. 2017;29:154‐158.
Sounouvou HT, Lechanteur A, Piel G, Evrard B. Silicones in dermatological topical drug formulation: overview and advances. Int J Pharm. 2022;625:122111.
Van Norman GA. Decentralized clinical trials. JACC Basic Transl Sci. 2021;6:384‐387.
Coates SJ, Kvedar J, Granstein RD. Teledermatology: from historical perspective to emerging techniques of the modern era: part I: history, rationale, and current practice. J Am Acad Dermatol. 2015;72:563‐574; quiz 575‐576.
Health, C. for D. and R. What is Digital Health? FDA; 2020.
Kabisch M, Ruckes C, Seibert‐Grafe M, Blettner M. Randomized controlled trials: part 17 of a series on evaluation of scientific publications. Dtsch Ärztebl Int. 2011;108:663‐668.
Guidance on the Implementation of Decentralised Elements in Clinical Trials with Medicinal Products is Now Available. Danish Medicines Agency. Accessed September 8, 2023. https://laegemiddelstyrelsen.dk/en/news/2021/guidance‐on‐the‐implementation‐of‐decentralised‐elements‐in‐clinical‐trials‐with‐medicinal‐products‐is‐now‐available/
EMA. Facilitating Decentralised Clinical Trials in the EU. European Medicines Agency; 2022. https://www.ema.europa.eu/en/news/facilitating‐decentralised‐clinical‐trials‐eu
Shortt N, Martin A, Kerse K, et al. Efficacy of a 3% Kānuka oil cream for the treatment of moderate‐to‐severe eczema: a single blind randomised vehicle‐controlled trial. EClinicalMedicine. 2022;51:101561.
Definition of Phase I/II Clinical Trial – NCI Dictionary of Cancer Terms – NCI; 2011. Accessed September 8, 2023. https://www.cancer.gov/publications/dictionaries/cancer‐terms/def/phase‐i‐ii‐clinical‐trial
Huang X, Biswas S, Oki Y, Issa J‐P, Berry DA. A parallel phase I/II clinical trial design for combination therapies. Biometrics. 2007;63:429‐436.
Ouellette S, Rao BK. Usefulness of smartphones in dermatology: a US‐based review. Int J Environ Res Public Health. 2022;19:3553.
Mowlem FD, Tenaerts P, Gwaltney C, Oakley‐Girvan I. Regulatory acceptance of patient‐reported outcome (PRO) data from bring‐your‐own‐device (BYOD) solutions to support medical product labeling claims: let's share the success stories to move the industry forward. Ther Innov Regul Sci. 2022;56:531‐535.
Ali Z, Zibert JR, Thomsen SF. Virtual clinical trials: perspectives in dermatology. Dermatology. 2020;236:375‐382.
Ali Z, Zibert JR, Thomsen SF. Decentralised clinical trials. Ugeskr Laeger. 2021;183:V05200378.
Mobile Devices in the Nordics. Statista. Accessed September 8, 2023. https://www.statista.com/topics/7189/mobile‐devices‐in‐the‐nordics/
Decentralised Clinical Trials. Healthcare Denmark. Accessed September 8, 2023. https://www.healthcaredenmark.dk/healthcare‐in‐denmark/population‐health‐management/decentralised‐clinical‐trials/
Ali Z, Chiriac A, Bjerre‐Christensen T, et al. Mild to moderate atopic dermatitis severity can be reliably assessed using smartphone‐photographs taken by the patient at home: a validation study. Skin Res Technol. 2022;28:336‐341. doi:10.1111/srt.13136
Ali Z, Joergensen KM, Andersen AD, et al. Remote rating of atopic dermatitis severity using photo‐based assessments: proof‐of‐concept and reliability evaluation. JMIR Form Res. 2021;5:e24766.
Ali Z, Joergensen KM, Vestergaard C, et al. Effective clinical study recruitment of patients with atopic dermatitis through social media. J Eur Acad Dermatol Venereol. 2021;35:e922‐e923.
Ortner VK, Johansen B, Kilov K, et al. The Copenhagen actinic keratosis study (COAKS). A decentralised clinical trial to evaluate tolerability, safety and efficacy of daily field‐directed topical treatment with cytosolic phospholipase A2 inhibitor, AVX001, in participants with actinic keratosis: protocol for a randomised controlled phase I/IIa trial. BMJ Open. 2022;12:e061012.
Rosen R, Marmur E, Anderson L, Welburn P, Katsamas J. A new, objective, quantitative scale for measuring local skin responses following topical actinic keratosis therapy with Ingenol Mebutate. Dermatol Ther. 2014;4:207‐219.
Accessed August 17, 2023. https://patents.google.com/patent/WO2018055058A1/en?oq=ep2017%2f073951
Answer piping – Google Surveys Help. Accessed September 8, 2023. https://support.google.com/surveys/answer/6004246?hl=en
Konstantinidis D, Iliakis P, Tatakis F, et al. Wearable blood pressure measurement devices and new approaches in hypertension management: the digital era. J Hum Hypertens. 2022;36:945‐951. doi:10.1038/s41371-022-00675-z
Boissin C, Fleming J, Wallis L, Hasselberg M, Laflamme L. Can we trust the use of smartphone cameras in clinical practice? Laypeople assessment of their image quality. Telemed J E Health. 2015;21:887‐892.
Ortner VK, Mandel VD, Skak K, et al. Investigating the efficacy and safety of calcipotriol/betamethasone dipropionate foam and laser microporation for psoriatic nail disease‐a hybrid trial using a smartphone application, optical coherence tomography, and patient‐reported outcome measures. Dermatol Ther. 2022;35:e15965.
Jalaboi R, Winther O, Galimzianova A. Explainable image quality assessments in teledermatological photography. Telemed J E Health. 2023;29:1342‐1348. doi:10.1089/tmj.2022.0405